Cancer
Hedgehog pathway inhibitors (vismodegib)
Drugs that block Smoothened, the switch of the Hedgehog pathway, which is abnormally active in nearly all basal cell carcinomas; used when the tumour is locally advanced or metastatic and cannot be treated by surgery or radiotherapy.
Mécanisme d’action
- Normally PTCH1 restrains Smoothened (SMO); Hedgehog ligand releases it, activating GLI transcription factors.
- In basal cell carcinoma, loss of PTCH1 (or activating SMO mutations) switches the pathway on permanently.
- Vismodegib and sonidegib bind and inhibit SMO, switching off GLI-driven growth.
Cibles moléculaires
- Smoothened (SMO): Antagonist
Médicaments : Hedgehog pathway inhibitors (vismodegib)
- Vismodegib (By mouth.)
- Sonidegib
Indications thérapeutiques
- Locally advanced basal cell carcinoma not suitable for surgery or radiotherapy
- Metastatic basal cell carcinoma
Maladies traitées
Effets indésirables
- Muscle spasms
- Hair loss
- Loss of taste and weight loss
- Fatigue
Contre-indications selon le terrain
- Pregnancy (Contre-indiqué): Hedgehog signalling patterns the embryo: severe birth defects or fetal death. Strict contraception for both sexes, and no blood donation.
- Breastfeeding (Contre-indiqué): It may harm the infant.
Rédigé d’après
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, Hedgehog pathway inhibitors
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 61, Dermatologic Pharmacology, Basal cell carcinoma: hedgehog inhibitors
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.